Three nurses discuss the differences in the care and education required for patients with first-line EGFR-mutated non–small cell lung cancer.
|Articles|November 1, 2006
- ONCOLOGY Vol 20 No 13
- Volume 20
- Issue 13
Novel Molecular Therapies Appendix
appendix
Advertisement
Download the Appendix as a PDF.
Articles in this issue
almost 20 years ago
Acute Myeloid Leukemia in the Elderly: A Unique Diseasealmost 20 years ago
Adjuvant Therapy for Early Lung Cancer: Reflections and Perspectivesalmost 20 years ago
What Defines an 'Elderly Patient With AML'?almost 20 years ago
Thirty Years Later: We've Only Just Begunalmost 20 years ago
Progress With a Purpose: Eliminating Suffering and Death Due to Canceralmost 20 years ago
Teleoncology Extends Access to Quality Cancer Carealmost 20 years ago
Does This Woman Have Gestational Trophoblastic Disease?almost 20 years ago
Managing Acute Myeloid Leukemia in the ElderlyAdvertisement
Related to this article
Elizabeth Thompson, MD, discusses pediatric cancer, proton therapy, and her work as a peer reviewer for CURiE.
![“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c7abebf9344f9b1be9aee80d9879d139c1655bcc-1200x1197.jpg?w=350&fit=crop&auto=format)
“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.
Pieter Sonneveld, MD, PhD, explained how sustained MRD negativity with DVRd in the PERSEUS trial may guide long-term outcome counseling in multiple myeloma.
Time to worsening of symptoms was improved with amivantamab plus chemotherapy compared with chemotherapy alone in the phase 3 PAPILLON trial.
The FDA granted priority review to perioperative durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive disease, based on phase 3 VOLGA data.
Longer follow-up is needed for the phase 3 MIDAS trial to determine the impact of MRD conversion on progression-free survival and overall survival.
The FDA cleared TriSalus’s TriNav Advance device, which extends the SmartValve-based drug delivery technology to improve tumor penetration during liver embolization.
Advertisement
Advertisement
Trending on CancerNetwork
1
Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC
2
Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC
3
FDA Clears TriNav Advance for Expanded Liver Embolization Access
4
Cevostamab Combo Shows Durable Responses in R/R Multiple Myeloma
5